New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
08:07 EDTESI, ABBV, ABT, FII, NCIT, DELLAbbVie to join S&P 100, 500 in place of Dell, Federated Investors
S&P Dow Jones Indices announced last night that it will make the following changes to the S&P 100, 500, MidCap 400 and SmallCap 600 indices after the close of trading on Monday, December 31: AbbVie (ABBV) will replace Dell (DELL) in the S&P 100, and Federated Investors (FII) in the S&P 500. Federated will replace ITT Educational Services (ESI) in the S&P MidCap 400, and ITT Educational Services will replace NCI Inc. (NCIT) in the S&P SmallCap 600. S&P 100 and 500 constituent Abbott (ABT) is spinning off AbbVie in a transaction expected to be completed after the close of trading on December 31. Abbott will remain in the S&P 100 and 500.
News For ABBV;DELL;FII;ESI;NCIT;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
14:07 EDTABBVProPublica says Medicare spent $4.5B on hepatitis C treatments last year
Subscribe for More Information
10:24 EDTABTMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
09:27 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTABTTeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTABTMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
March 27, 2015
07:07 EDTABBVBiogen, AbbVie say EMA validates MAA for Zinbryta for treatment of MS
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the companies’ Marketing Authorisation Application for ZINBRYTA for the treatment of relapsing forms of multiple sclerosis in the European Union. Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA’s Committee for Medicinal Products for Human Use. The MAA included results from two clinical trials, DECIDE and SELECT, in which ZINBRYTA 150 mg was administered subcutaneously every four weeks in people with relapsing-remitting MS. Biogen and AbbVie are jointly developing ZINBRYTA.
March 26, 2015
16:39 EDTESIBlum Capital lowers stake in ITT Educational to 5% from 6.1%
March 23, 2015
09:03 EDTABBVLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
09:03 EDTABTFiserv says Abbott employee credit union expands partnership
Subscribe for More Information
07:17 EDTABBVAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
12:02 EDTFIIFederated Investors to acquire $91M in assets from Touchstone Ohio
Subscribe for More Information
08:31 EDTFIIFederated Investors to acquire $91M in assets from Touchstone Ohio
Federated Investors and Touchstone Advisors have reached a definitive agreement regarding the acquisition by Federated of certain assets relating to Touchstone's management of the Touchstone Ohio Tax-Free Money Market Fund, a series of Touchstone Tax-Free Trust. In connection with the acquisition, approximately $91M in tax-free money market assets will be reorganized from the Touchstone Ohio Tax-Free Money Market Fund into Federated Ohio Municipal Cash Trust, a portfolio with a similar investment objective. Federated Ohio Municipal Cash Trust has approximately $391M in net assets and is a portfolio of the Federated Money Market Obligations Trust, which has approximately $184B in aggregate net assets. With approximately $19B in tax-free, state-specific money market assets under management, Federated offers more tax-free state money market products than any other investment manager. The reorganization is expected to be tax-free and is anticipated to be completed in the second quarter of 2015. Closing of the transaction is subject to shareholder approval and certain other contingencies.
07:41 EDTABBVAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
08:47 EDTABBVAbbVie and C2N sign worlwide license agreement for Alzheimer's Disease therapy
AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. Financial terms of the collaboration were not disclosed.
07:56 EDTABBVAbbVie plans $30M expansion at plant in Puerto Rico, AP reports
AbbVie is planning to expand one of its facilities in Barceloneta, Puerto Rico, The Associated Press reports. The $30M expansion is slated for a plant that manufactures products related to immunology, virology and metabolic disorders. Reference Link
March 18, 2015
07:33 EDTESIITT Educational receives notice from NYSE on late filing status
ITT Educational Services announced that it did not file its Annual Report on Form 10-K for the fiscal year ended December 31, 2014 on or before the due date of March 16, 2015. The company has received a notice from the NYSE that the company is subject to the NYSE's procedures under its timely filing criteria as a result of the company's failure to file the 2014 Form 10-K by the due date. Under NYSE rules, the company has six months from March 16, 2015 to file the 2014 Form 10-K. Until the company files the 2014 Form 10-K and all other periodic reports with subsequent due dates, its common stock will remain listed on the NYSE under the symbol "ESI," with a "LF" indicator to signify late filing status. The company can regain compliance with the NYSE listing standards during the six-month period once it files the 2014 Form 10-K with the SEC, but only if it has also filed all other periodic reports with subsequent due dates. The company is still evaluating the full impact of the consolidation of the 2009 Entity on these matters, and therefore cannot provide any assurance that the consolidation of 2009 Entity will not have a material negative impact on these matters, which could result in a material adverse effect on the company's results of operations, financial condition and/or cash flows. Further, the company did anticipate that it may be in noncompliance with certain covenants under its financing agreement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use